# FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer

> **NCT01133990** · PHASE1,PHASE2 · TERMINATED · sponsor: **Eisai Inc.** · enrollment: 5 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** FOLFIRI
- **DRUG:** E7820
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT01133990
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-03-04
- **Primary completion:** 2011-02-18
- **Final completion:** 2011-02-18
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** The study was terminated early as the combination of E7820 and FOLFIRI was deemed to be not tolerable, hence no efficacy analysis was conducted.
- **Last updated:** 2023-11-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01133990

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01133990, "FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01133990. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*